JPRN-UMIN000011308已完成3 期
A Placebo Controlled Phase III Double Blind Study of ITK-1 in Patients with Prostate Cancer - A Clinical Evaluation of ITK-1 in Castration-Resistant, Docetaxel Refractory Prostate Cancer Patients with HLA-A24 positive <Confirmatory Study> - - A Placebo Controlled Phase III Double Blind Study of ITK-1 in Patients with Prostate Cancer
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 333
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 85years-old（—）
- 性别
- Male
入选标准
- 未提供
排除标准
- •1.Received the Taxane antitumor agents except for Docetaxcel 2. Hypersensitivity to mineral oil or mannitol oleate 3. Severe complications 4. Active multiple cancers 5. Received ITK-1 in the past 6. Entry to the other clinical trial within 2 months prior to entry to this study 7. Difficult to participate in this trial because of psychiatric symptoms 8. The patient who is suspected to suffer from any improper disadvantages by not participating in this study 9. Any other cases who are judged as being ineligible for this study by physician
研究者
相似试验
招募中
2 期
to Evaluate Efficacy and Safety of Emotional discouragement capsules in Individuals presenting with mild occasional emotional discouragementCTRI/2018/05/013614The Himalaya Drug Company
进行中（未招募）
不适用
A Phase 2a, Double Blind, Placebo Controlled Study of the Efficacy, Safety and Tolerability of 6-week Treatment With ALV003 In Patients With Well-Controlled Celiac DiseaseMedDRA version: 9.1Level: LLTClassification code 10007864Term: Celiac diseaseCeliac DiseaseEUCTR2009-012221-10-FIAlvine Pharmaceuticals, Inc.107
进行中（未招募）
1 期
A controlled study to assess the safety, tolerability, and efficacy of the study drug, ISIS 766720, in patients with acromegaly (a hormonal disorder that results from too much growth hormone in the body)EUCTR2017-004259-22-ROIonis Pharmaceuticals, Inc.42
进行中（未招募）
1 期
A controlled study to assess the safety, tolerability, and efficacy of the study drug, ISIS 766720, in patients with acromegaly (a hormonal disorder that results from too much growth hormone in the body)Acromegaly is a chronic disorder caused by GH hypersecretion, most commonly as a result of a GH-secreting pituitary adenoma.MedDRA version: 20.0 Level: PT Classification code 10000599 Term: Acromegaly System Organ Class: 10014698 - Endocrine disordersEUCTR2017-004259-22-CZIonis Pharmaceuticals, Inc.42
进行中（未招募）
1 期
A controlled study to assess the safety, tolerability, and efficacy of the study drug, ISIS 766720, in patients with acromegaly (a hormonal disorder that results from too much growth hormone in the body)Acromegaly is a chronic disorder caused by GH hypersecretion, most commonly as a result of a GH-secreting pituitary adenoma.MedDRA version: 20.0Level: PTClassification code 10000599Term: AcromegalySystem Organ Class: 10014698 - Endocrine disordersEUCTR2017-004259-22-ATIonis Pharmaceuticals, Inc.42